Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block
NCT03460509Phase 4Unknown
- Sponsor
- Sykehuset i Vestfold
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Sykehuset i Vestfold. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03460509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460509.